Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
2018 · EBioMedicine · 77 citations
https://doi.org/10.1016/j.ebiom.2018.02.001
E
Erika Aldeguer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
46
Papers
616
Citations
10
h-index
10
i10-index
Erika Aldeguer is an academic researcher. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics & Cancer Immunotherapy and Biomarkers. The author has an h-index of 10, co-authored 40 publications.
Papers by this author
worksIntegrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
2018 · EBioMedicine · 44 citations
https://doi.org/10.1016/j.ebiom.2018.11.036
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
2018 · Journal of Translational Medicine · 28 citations
https://doi.org/10.1186/s12967-017-1352-z
BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
2020 · JTO Clinical and Research Reports · 9 citations
https://doi.org/10.1016/j.jtocrr.2020.100113
Detection of Somatic Alterations in Peritoneal Lavages of Early-Stage Endometrial Carcinoma Patients
2023 · The Journal of Liquid Biopsy · 0 citations
https://doi.org/10.1016/j.jlb.2023.100099
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat